Roman Akasov
Overview
Explore the profile of Roman Akasov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasnovskaya O, Spector D, Bykusov V, Isaeva Y, Akasov R, Zharova A, et al.
ChemMedChem
. 2025 Jan;
:e202400786.
PMID: 39791228
Light induced release of cisplatin from Pt(IV) prodrugs is a promising tool for precise spatiotemporal control over the antiproliferative activity of Pt-based chemotherapeutic drugs. A combination of light-controlled chemotherapy (PACT)...
2.
Spector D, Bubley A, Zharova A, Bykusov V, Skvortsov D, Ipatova D, et al.
ACS Appl Bio Mater
. 2024 May;
7(5):3431-3440.
PMID: 38697834
Light-induced release of cisplatin from Pt(IV) prodrugs represents a promising approach for precise control over the antiproliferative activity of Pt-based chemotherapeutic drugs. This method has the potential to overcome crucial...
3.
Attia M, Akasov R, Elbaz N, Owens T, Curtis E, Panda S, et al.
ACS Appl Mater Interfaces
. 2022 Nov;
14(49):54389-54400.
PMID: 36449986
Here, we report the synthesis of robust hybrid iodinated silica-lipid nanoemulsions (HSLNEs) for use as a contrast agent for ultrasound and X-ray applications. We engineered iodinated silica nanoparticles (SNPs), lipid...
4.
Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine
Parodi A, Kolesova E, Voronina M, Frolova A, Kostyushev D, Trushina D, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362156
The ultimate goal of nanomedicine has always been the generation of translational technologies that can ameliorate current therapies. Cancer disease represented the primary target of nanotechnology applied to medicine, since...
5.
Parodi A, Kostyushev D, Brezgin S, Kostyusheva A, Borodina T, Akasov R, et al.
Semin Cancer Biol
. 2022 Apr;
86(Pt 2):555-567.
PMID: 35472397
With the ultimate goal of increasing tumor accumulation of therapeutics, various nanocarriers have been designed to overcome biological barriers encountered at each stage, from drug administration to the cancerous lesion....
6.
Akasov R, Khaydukov E, Yamada M, Zvyagin A, Leelahavanichkul A, Leanse L, et al.
Adv Drug Deliv Rev
. 2022 Mar;
184:114198.
PMID: 35301045
No abstract available.
7.
Attia M, Swasy M, Akasov R, Alexis F, Whitehead D
ACS Appl Bio Mater
. 2022 Jan;
3(8):5067-5079.
PMID: 35021683
Lipid nanoemulsions (LNEs) are promising nanocarriers for delivering high payloads of lipophilic molecules. Nonetheless, the dynamic nature at their aqueous interfaces results in poor surface chemistry and thus ligand functionalization...
8.
Krasnovskaya O, Spector D, Erofeev A, Gorelkin P, Akasov R, Skvortsov D, et al.
Dalton Trans
. 2021 May;
50(23):7922-7927.
PMID: 34037020
In a recent research paper Dr. Suxing Jin et al. reported two multispecific PtIV complexes DNP and NP with non-steroidal anti-inflammatory drug naproxen (NPX) as the axial ligand(s). Herein, we...
9.
Ryabaya O, Abramov I, Khochenkov D, Akasov R, Sholina N, Prokofieva A
Invest New Drugs
. 2021 Mar;
39(4):987-1000.
PMID: 33683500
Objective The problem of drug resistance to BRAF-targeted therapy often occurs in melanoma treatment. Activation of PI3K/AKT/mTOR signaling pathway is one of the mechanisms of acquired resistance and a potential...
10.
Attia M, Akasov R, Alexis F, Whitehead D
ACS Biomater Sci Eng
. 2020 Dec;
6(12):6671-6679.
PMID: 33320612
We developed four types of -phenylene-bridged periodic mesoporous organosilica NPs (-P PMO NPs) with tailored physical parameters including size, morphology, porosity, and surface area using a new polymer-scaffolding approach. The...